Fate Therapeutics (NASDAQ:FATE) Stock Rating Reaffirmed by N

Needham & Company LLC restated their hold rating on shares of Fate Therapeutics (NASDAQ:FATE – Free Report) in a research report released on Thursday, Benzinga reports. A number of other equities analysts also recently issued reports on FATE. Oppenheimer reissued a market perform rating on shares of Fate Therapeutics in a report on Tuesday, February […]

Related Keywords

, Financial Services Group Inc , Advisor Group , Envestnet Asset Management Inc , Fate Therapeutics Inc , Raymond James Associates , Needham Company , Hightower Advisors , Barclays , Morgan Stanley , Fate Therapeutics , Free Report , Get Free Report , Asset Management , Tower Advisors , Services Group , Fate Therapeutics Daily , Nasdaq Fate , Fate , Medical , Reiterated Rating , Needham Company Llc ,